Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 12Phase NA 5Phase 1/2 4Phase 3 2Phase 4 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 16Gastrointestinal 14Lymphoid 13Thoracic 12CNS 12Other hematologic neoplasm 11Breast 9Sarcoma 7Gynecologic 7Head & Neck 6Dermatologic 4Other solid neoplasm 3Plasma cell 2Tumor-Agnostic 1NET 1Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 177Bortezomib 98Lenalidomide 90daratumumab 46Melphalan 45Thalidomide 44pomalidomide 42Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14ixazomib 11isatuximab 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Specimen Handling × Plasma cell × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03941860 2025-05-23

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

National Cancer Institute (NCI)

Phase 3 Completed
1 enrolled 1 chart
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡